Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
It is estimated that 350-400 million people have chronic infection with hepatitis B virus
(HBV) all over the world. In china, 93 million individuals suffer from this chronic
condition. Currently, seven medications are approved for the treatment of hepatitis B: two
formulations of interferon and four nucleos(t)ide analogues. The Chinese population has one
of the longer average life spans, and the size of the aged population has been increasing
rapidly. As a result, the prevalence of elderly patients with HBV has increased, and the
potential for development of cirrhosis or hepatocellular carcinoma in such patients is real.
Hence, treatment of elderly patients with HBV is an important issue. However, ADV or ETV has
become first choice due to the more side effect of INF and the resistant of LAM and LdT. But
treatment outcomes with ADV and ETV in elderly are not known yet. In this study, we will
evaluate and compare the efficacy and tolerability of ADV and ETV between younger and older
patients with HBV. The aims of the present study are (1)to assess the benefits of ADV or ETV
therapy for elderly patients with chronic hepatitis B, and (2)to determine differences in the
emergence rate of side effect.